Ventana gains access to Molecular's HPV (Human Papilloma Virus) test
This article was originally published in Clinica
Executive Summary
Ventana Medical Systems aims to add to its human papillomavirus (HPV) portfolio by acquiring a licence to Molecular Diagnostics' In-Cell HPV test for an undisclosed amount and royalties. The product is a bio-molecular assay for the detection of E6 and E7 HPV proteins.